Skip to content
Companies

Neutrolis

Enzymes that clear neutrophil traps in autoimmune disease

Raised to date

$4.5M

of $11M offered across 2 Form D filings

Still open
$6.5M
Investors
9
Last filed
Jul 15, 2025

About

Neutrolis Inc. is a clinical-stage biotechnology firm that specializes in developing innovative therapies aimed at autoimmune and inflammatory diseases. The company's unique approach focuses on targeting Neutrophil Extracellular Traps (NETs), which are implicated in tissue damage and chronic inflammation associated with several immune-mediated disorders, such as lupus and dry eye disease, as well as severe complications from conditions like COVID-19.

Neutrolis stands out by developing therapies that specifically target the harmful effects of NETs without broadly suppressing immune function.

Funding

$10M round, first sold Jun 2025$3.5M sold$6.5M still openFeb 20252026
Now
  • Security to be acquiredFiled Jul 15, 2025Form D
    $3.5M/ $10M
  • EquityFiled Apr 8, 2025Form D
    $965K/ $1M

Product

exDNASE™ platform

Biopharmaceuticals

The exDNASE™ platform is Neutrolis’s proprietary technology designed to engineer enzymes specifically for the degradation of Neutrophil Extracellular Traps (NETs). This platform is pivotal in developing therapies that can mitigate the damaging effects of overactive neutrophils in autoimmune and inflammatory diseases.

  • Engineered enzymes targeting NETs
  • First-in-class therapeutic solutions
  • Non-immunosuppressive treatment options

Built for

Patients with autoimmune diseases and inflammatory disorders

People on file